Positive Phase III Results Show Xofluza Significantly Reduces the ...
WEB6 days ago · The most common side effects of XOFLUZA for treatment of the flu in adults and adolescents (12 years of age and older) were diarrhea, bronchitis, nausea, sinusitis, and headache.
Roche Antiviral Drug Reduces Transmission in Late-stage Study
WEB5 days ago · Xofluza is approved in several countries for the treatment of uncomplicated influenza types A and B. Year to date, Roche’s shares have risen 9% compared with the industry’s 24.8% growth. Zacks ...
Positive Phase III Results Show Xofluza Significantly Reduces the ...
WEB6 days ago · SOUTH SAN FRANCISCO, Calif., September 19, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of ...
Positive phase III results show Xofluza significantly - GlobeNewswire
WEB6 days ago · Xofluza is approved in more than 80 countries for the treatment of uncomplicated influenza types A and B. 10 In Europe, Xofluza is approved for the treatment of influenza in otherwise healthy ...
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, …
WEB5 days ago · On Thursday, Roche Holdings AG (OTC: RHHBY) released positive topline results of the phase 3 CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral that showed a reduction in the ...
Roche’s Xofluza reduces flu transmission in Phase 3 study
WEB6 days ago · Dive Brief: Roche’s antiviral drug Xofluza reduced influenza transmission among household contacts in a large Phase 3 study, the company said Wednesday. Treatment with a single dose of Xofluza within 48 hours of symptom onset lowered the likelihood an infected person passed on the virus to …
Roche announces U.S. FDA approval of Xofluza to treat
WEBAug 12, 2022 · In the United States (US), Xofluza is approved for the treatment of acute, uncomplicated influenza in patients aged 12 years and above who are otherwise-healthy or at high-risk of developing...
FDA approves new drug to treat influenza | FDA - U.S. Food and …
WEBFDA approved Xofluza (baloxavir marboxil) to treat acute uncomplicated flu in patients 12 years old and older who have been symptomatic for less than 48 hours.
FDA Expands Approval of Influenza Treatment to Post-Exposure …
WEBNov 23, 2020 · Today, the U.S. Food and Drug Administration expanded the approved indication for Xofluza (baloxavir marboxil) to include post-exposure prevention of influenza (flu) for patients 12 years of...
Genentech Announces FDA Approval of Xofluza to Treat Influenza …
WEBAug 11, 2022 · Xofluza is a first-in-class, single-dose oral medicine with an innovative proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro...